1
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Condition(s):Atypical Hemolytic Uremic Syndrome (aHUS)Last Updated:April 18, 2023Completed
Complement Inhibitor: 289 Clinical Trials, Page 1 of 29
Hide Studies Not Open or Pending
2
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition(s):Paroxysmal Nocturnal Hemoglobinuria (PNH)Last Updated:May 6, 2023Completed
3
Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy
Condition(s):Paroxysmal Nocturnal Hemoglobinuria (PNH)Last Updated:May 11, 2023Completed
4
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
Condition(s):Complement Mediated DiseasesLast Updated:January 16, 2018Completed
5
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy
Condition(s):Atypical Hemolytic Uremic SyndromeLast Updated:May 16, 2023Recruiting
6
A Phase III Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.
Condition(s):Paroxysmal Nocturnal HemoglobinuriaLast Updated:May 11, 2023Active, not recruiting
7
A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
Condition(s):Paroxysmal Nocturnal HemoglobinuriaLast Updated:May 11, 2023Recruiting
8
Ravulizumab-Controlled Non-Inferiority Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy
Condition(s):Paroxysmal Nocturnal HemoglobinuriaLast Updated:March 3, 2023Recruiting
9
Complement Inhibitor Eculizumab in Clinical Islet Transplantation
Condition(s):Diabetes MellitusLast Updated:October 4, 2018Completed
10
A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH
Condition(s):PNH; HemolysisLast Updated:September 14, 2022Recruiting